Turbulent US insulin market to force 3,000 layoffs at Novo Nordisk

11 June 2018

Danish diabetes giant Novo Nordisk (NOV: N) is to fire 3,000 staff and reduce long-term growth projections, in an increasingly challenging pricing environment for insulin.

Shares in the firm dipped after local press reported that management is looking at where the axe should fall, with the intention of announcing the cost-saving measures in the company’s second quarterly report.

The planned cut to long-term growth projections was reportedly due to ‘uncertain and unpredictable’ market factors. In 2016 Novo Nordisk was forced to fire 1,000 if its staff and lower long-term guidance from 15% down to 5%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK